360 related articles for article (PubMed ID: 9743346)
1. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
2. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor.
Rosenberg JS; Oshima M; Atassi MZ
J Immunol; 1996 Oct; 157(7):3192-9. PubMed ID: 8816433
[TBL] [Abstract][Full Text] [Related]
3. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
Balasa B; Deng C; Lee J; Bradley LM; Dalton DK; Christadoss P; Sarvetnick N
J Exp Med; 1997 Aug; 186(3):385-91. PubMed ID: 9236190
[TBL] [Abstract][Full Text] [Related]
4. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
[TBL] [Abstract][Full Text] [Related]
5. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
6. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
7. Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors.
Bellone M; Ostlie N; Lei S; Conti-Tronconi BM
Eur J Immunol; 1991 Oct; 21(10):2303-10. PubMed ID: 1680694
[TBL] [Abstract][Full Text] [Related]
8. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
9. The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor.
Bellone M; Ostlie N; Lei SJ; Wu XD; Conti-Tronconi BM
J Immunol; 1991 Sep; 147(5):1484-91. PubMed ID: 1715360
[TBL] [Abstract][Full Text] [Related]
10. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.
Baggi F; Andreetta F; Caspani E; Milani M; Longhi R; Mantegazza R; Cornelio F; Antozzi C
J Clin Invest; 1999 Nov; 104(9):1287-95. PubMed ID: 10545527
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis.
Huang D; Shi FD; Giscombe R; Zhou Y; Ljunggren HG; Lefvert AK
Eur J Immunol; 2001 Jan; 31(1):225-32. PubMed ID: 11265638
[TBL] [Abstract][Full Text] [Related]
13. Induction of interferon-gamma, interleukin-4, and transforming growth factor-beta in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Ljungdahl A; Höjeberg B; Link J; He B; Qiao J; Melms A; Olsson T
Cell Immunol; 1994 Sep; 157(2):353-68. PubMed ID: 7520837
[TBL] [Abstract][Full Text] [Related]
14. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.
Karachunski PI; Ostlie NS; Monfardini C; Conti-Fine BM
J Immunol; 2000 May; 164(10):5236-44. PubMed ID: 10799884
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.
Lobito AA; Yang B; Lopes MF; Miagkov A; Adams RN; Palardy GR; Johnson MM; McFarland HI; Recher M; Drachman DB; Lenardo MJ
Eur J Immunol; 2002 Jul; 32(7):2055-67. PubMed ID: 12115627
[TBL] [Abstract][Full Text] [Related]
16. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
17. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice.
Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA
J Immunol; 1992 Jun; 148(11):3385-90. PubMed ID: 1375242
[TBL] [Abstract][Full Text] [Related]
18. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.
Paas-Rozner M; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12642-7. PubMed ID: 11606745
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
Atassi MZ; Oshima M
Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
